SCHEMBL5539306

SCHEMBL5539306

FC(F)(F)Oc1cc(NCCc2cc[c]cc2)cc(OC(F)(F)F)c1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RORC P51449 1/20 0.38
CYP3A4 P08684 1/20 0.35
EPHX2 P34913 2/20 0.35
LTA4H P09960 1/20 0.35
CNR1 P21554 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
MAPT P10636 3/20 0.35
TRPV1 Q8NER1 2/20 0.34
NRP1 O14786 1/20 0.34
PPARA Q07869 1/20 0.33
DAO P14920 1/20 0.33
CNR2 P34972 2/20 0.33
GPR84 Q9NQS5 1/20 0.32
MEN1 O00255 1/20 0.32
HTT P42858 1/20 0.32
RAB9A P51151 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5535515 0.83 MAPT (0.45) CYP3A4EPHX2LTA4HL3MBTL1MAPT
SCHEMBL5546744 0.78 CNR1 (0.51) CNR1TRPV1DAO
SCHEMBL5540131 0.78 MAPT (0.43) CYP3A4EPHX2LTA4HL3MBTL1MAPT
SCHEMBL5545414 0.75 MAPT (0.40) EPHX2LTA4HMAPTTRPV1DAO
SCHEMBL5537388 0.72 MAPT (0.52) CYP3A4EPHX2L3MBTL1MAPTPPARA
SCHEMBL6232154 0.72 CHRNA7 (0.42) EPHX2L3MBTL1MAPTMEN1HTT
SCHEMBL6555806 0.72 L3MBTL1 (0.47) CNR1L3MBTL1MAPTGPR84MEN1
SCHEMBL5546035 0.72 MAPT (0.43) CYP3A4EPHX2LTA4HL3MBTL1MAPT
SCHEMBL5539336 0.71 FFAR1 (0.47) RORCEPHX2CNR1L3MBTL1MAPT
SCHEMBL29133542 0.71 TRPV1 (0.65) EPHX2LTA4HTRPV1PPARAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 RORC 19/4885CYP3A4 1683/4885EPHX2 3662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.